multiple sclerosis market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Investment for Healthcare Infrastructure
   3. Market Restraints
      1. High Treatment Costs
      2. Limited Efficacy in Progressive Forms
   4. Market Opportunities
      1. Rising Investment for the Development of Advanced Technologies
   5. Market Trends
      1. Shift Towards Personalized Medicine
      2. Focus on Neuroprotection and Repair Therapies
5. MARKET SEGMENTATION
   1. By Type
      1. Clinically isolated syndrome (CIS)
      2. Relapse-remitting MS (RRMS)
      3. Primary progressive MS (PPMS)
      4. Secondary progressive MS (SPMS)
   2. By Treatment
      1. Medications
      2. Stem Cell Therapy
      3. Physical Therapy
      4. Plasma Exchange
      5. Others
   3. By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
   4. By Diagnosis
      1. Magnetic Resonance Imaging (MRI)
      2. Simple Electrical Stimulation Tests
      3. Lumbar Puncture
      4. Others
   5. By Route of Administration
      1. Oral
      2. Parenteral
      3. Others
   6. By End-Users
      1. Hospitals
      2. Specialty Clinics
      3. Homecare
      4. Others
   7. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
      4. Others
   8. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Actelion Pharmaceuticals Ltd (Switzerland)
      2. Allergan (Ireland)
      3. Abbott (US)
      4. AstraZeneca (UK)
      5. AbbVie Inc. (US)
      6. Bayer AG (Germany)
      7. Bayer AG (Germany)
      8. Cipla Inc. (US)
      9. Eli Lilly and Company (US)
      10. F. Hoffmann-La Roche Ltd. (Switzerland)
      11. GlaxoSmithKline plc (UK)
      12. Johnson & Johnson Private Limited (US)
      13. Mylan N.V. (US)
      14. Merck KGaA (Germany)
      15. Merck & Co., Inc. (US)
      16. Novartis AG (Switzerland)
      17. Opexa Therapeutics, Inc. (US)
      18. Pfizer Inc. (US)
      19. Sanofi (France)
      20. Teva Pharmaceutical Industries Ltd.(Jerusalem)

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Multiple Sclerosismarket?

The global market of Multiple Sclerosis is projected to reach USD 38.1Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Multiple Sclerosismarket?

The global Multiple Sclerosis market has an estimated annual growth rate of 3.7% .

Q.3. What are the recent trends of Multiple Sclerosismarket?

Shift towards personalized medicine and focus on neuroprotection and repair therapies are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Multiple Sclerosis?

The major companies profiled in this report include Actelion Pharmaceuticals Ltd (Switzerland), Allergan (Ireland), Abbott (US), AstraZeneca (UK), AbbVie Inc. (US), Bayer AG (Germany), Bayer AG (Germany), Cipla Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (UK), Johnson & Johnson Private Limited (US), Mylan N.V. (US), Merck KGaA (Germany), Merck & Co., Inc. (US), Novartis AG (Switzerland), Opexa Therapeutics, Inc. (US), Pfizer Inc. (US), Sanofi (France), Teva Pharmaceutical Industries Ltd.(Jerusalem), among others.

Q.5. Which region is estimated to held highest CAGR inMultiple Sclerosismarket?

North America is estimated to hold biggest share in the market for Multiple Sclerosis.